Establishment of the single EAEU market remains one of the most discussed topics in the context of good practices development. In this respect, the V All-Russian GMP Conference initiated a…
The list of important partners includes PRO.MED.CS Praha a.s., a leading Czech pharmaceutical company supplying its products to 26 countries. Mainly, it supplies its products to the Russian Federation, countries of the Central and Eastern Europe and the Middle East. The company has its own scientific and research base and specialises in the production of final dosage forms used to treat the digestive, cardiovascular and nervous systems. The main mission of the company, as PRO.MED.CS Praha a.s. sees it, is to provide patients with tested and safe drugs at a reasonable price.
Despite the fact that the coronavirus prevails in the media space, we should not forget that the risk of influenza infection is still here.
The All-Russian GMP Conference with international participation pays special attention to the development of innovations and advanced approaches to the organisation of pharmaceuticals and medical equipment production.
The COVID-19 pandemic has posed a number of challenges to the entire economy, state and society. The year 2020 is not an easy one also for the pharmaceutical industry that found itself in the epicentre of the fight against the pandemic. In this context, the V All-Russian GMP Conference participants will pay much attention to the matters of development in these new conditions.
Agreement will significantly increase global supply capacity for Lilly’s potential COVID-19 treatments.
On October 1, a master class titled New Formats of GMP Inspection is to take place within the V All-Russian GMP Conference. The block Practice. New Formats of GMP Inspection:…
Abbott is one of the largest global diversified healthcare companies operating in 160 countries. In Russia, Abbott was one of the first foreign investors when it started baby food production here more than 40 years ago.
Continuous production has become an urgent issue recently. This is a best practice that enables to optimize production, and introduce pharmaceutical products of uniform quality meeting all GMP requirements.